Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response
- PMID: 7065839
- DOI: 10.1001/archpsyc.1982.04290030011002
Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response
Abstract
Acute behavioral response to 20 mg of dextroamphetamine (intravenous) predicted fourth-week antipsychotic response to double-blind pimozide treatment. Patients whose psychotic condition improved with dextroamphetamine administration showed more antipsychotic response to pimozide therapy than those whose condition worsened or did not change. Multiple regression analysis indicated amphetamine-induced response predicted pimozide response after four weeks for fifth-week pimozide response was more accurately predicted by prepimozide psychosis ratings. Our study provides some evidence that mechanisms underlying early and late pimozide response are not necessarily identical. Because patients who did not respond to dextroamphetamine administration still improved with pimozide therapy, our data do not support the concept that schizophrenia can be divided into two groups (dopamine-sensitive or dopamine-insensitive) but, rather, that dopamine responsiveness changes over time. Clinical application is not warranted until studies with larger samples have replicated our findings.
Similar articles
-
Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia.Arch Gen Psychiatry. 1982 Mar;39(3):275-81. doi: 10.1001/archpsyc.1982.04290030017003. Arch Gen Psychiatry. 1982. PMID: 6802100 Clinical Trial.
-
Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment.Biol Psychiatry. 1982 Feb;17(2):233-42. Biol Psychiatry. 1982. PMID: 7074181
-
Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients.Arch Gen Psychiatry. 1980 Mar;37(3):287-90. doi: 10.1001/archpsyc.1980.01780160057006. Arch Gen Psychiatry. 1980. PMID: 6102456 Clinical Trial.
-
The role of pimozide in clinical psychiatry: a review.J Clin Psychiatry. 1991 May;52(5):221-33. J Clin Psychiatry. 1991. PMID: 2033030 Review.
-
Clinical uses of pimozide.South Med J. 1993 Mar;86(3):344-9. doi: 10.1097/00007611-199303000-00019. South Med J. 1993. PMID: 8451677 Review.
Cited by
-
Pimozide for schizophrenia or related psychoses.Cochrane Database Syst Rev. 2013 Nov 5;2013(11):CD001949. doi: 10.1002/14651858.CD001949.pub3. Cochrane Database Syst Rev. 2013. PMID: 24194433 Free PMC article.
-
Amphetamines for schizophrenia.Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD004964. doi: 10.1002/14651858.CD004964. Cochrane Database Syst Rev. 2004. PMID: 15495131 Free PMC article.
-
Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia.Psychopharmacology (Berl). 1985;87(1):111-5. doi: 10.1007/BF00431789. Psychopharmacology (Berl). 1985. PMID: 3933028 Clinical Trial.
-
Provocative tests with psychostimulant drugs in schizophrenia.Psychopharmacology (Berl). 1987;91(4):415-33. doi: 10.1007/BF00216006. Psychopharmacology (Berl). 1987. PMID: 2884687
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical